| 查看: 720 | 回复: 1 | |||
[交流]
JCR一区Frontiers in Pharmacology肝病方向专题邀稿（影响因子5.988）已有1人参与
|
|
frontiers in pharmacology, jcr药学一区、中科院大类医学二区，小类药学二区，影响因子5.988 ，citescore： 6.6 肝病方向专题：pathophysiology and pharmacological treatments associated with liver failures，https://www.frontiersin.org/rese ... with-liver-failures abstract submission deadline: 30 june 2023, manuscript submission deadline: 02 october 2023 可以与期刊协商提供相应的文章处理费豁免，欢迎各位老师同学投稿！ pathophysiology and pharmacological treatments associated with liver failures. about this research topic: acute and chronic liver failures, which represent the loss of liver function, occupy the center stage of hepatic disorders as they are connected with a variety of liver diseases including fatty liver disease, cirrhosis, viral hepatitis, hepatocellular carcinoma and hepatic encephalopathy. the clinical manifestations of liver failures are multifaceted and usually include fatigue, diarrhea, confusion, excess bleeding, and eventually death. in many cases, the only curative treatment option is liver transplantation. although it is generally accepted that liver failures occur under the influence of miscellaneous factors, the detailed molecular mechanisms of various liver failures and associated diseases have not been fully elucidated. since acute and chronic liver failures are major causes of morbidity and mortality globally, a detailed understanding of their associated pathogenesis is essential to improve the treatment options and outcomes in the context of limited liver transplantation. currently, severe toxic, metabolic, viral, and autoimmune injuries are the mainstream theories regarding the causes of acute and chronic liver failures. reducing and limiting the influence of relevant precipitating factors, thus, are the main strategies for the treatment of liver failure-associated disorders. over the last decade, there is also emerging evidence indicating the contribution of aging, mitochondrial damage, cellular senescence, and autophagy inhibition in the development of liver failures. this research topic will try to shed light on novel research elucidating the molecular and cellular pathogenesis of various liver diseases, as well as relevant intervention strategies. the aim is to bring together the latest findings on the pathogenesis mechanisms of liver failure-associated diseases and to propose future treatment strategies for acute and chronic liver failures. the topic editors encourage researchers to submit original researches, brief research reports, systematic reviews, reviews, mini-reviews, and clinical trials relevant to the pathogenesis and management of liver diseases, including, but not limited to the following themes: 1. pathophysiology, pharmacology and intervention strategies of acute and chronic liver failures. 2. pathophysiology, pharmacology and intervention strategies of fatty liver diseases. 3. pathophysiology, pharmacology and intervention strategies of hepatocellular carcinoma. 4. pathophysiology, pharmacology and intervention strategies of liver disease-associated neurological complications. why publish in our research topic? alongside a top group of authors, your work will be published in frontiers in pharmacology, a leading journal in the field with a journal impact factor of 5.988 and a citescore of 6.6. you can read more about the collection here: https://www.frontiersin.org/rese ... with-liver-failures please click the link to register your interest in submitting an article. we accept original researches, brief research reports, systematic reviews, reviews, mini-reviews, and clinical trials. the deadline for submission is 02/10/2023, but frontiers’ fast-track review process, led by my editorial team, means each article is published online as soon as it’s been successfully peer-reviewed and accepted (typically within 61 days). as an open access journal, publishing fees are applied to accepted articles. please contact pharmacology.submissions@frontiersin.org to discuss fees, institutional waivers, and discounts. the team at frontiers will be in touch over the next few days to explain more about contributing to the collection. if you have any other questions in the meantime, please let me know. i believe your insight will be a great addition to this topic, and i look forward to hearing more about your latest research. |
回复此楼» 猜你喜欢
一篇扩散模型的Nature Machine Intelligence论文和Elsevier上的深度学习药物书籍
已经有1人回复
-
FDA核查 研发机构
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有178人回复
-
国家高层次人才李兴淑教授课题组招收博士研究生
已经有39人回复
-
2026申博
已经有0人回复
-
合成
已经有0人回复
-
氨基酸的酰化反应，求大佬解答
已经有0人回复
-
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
-
己酮可可碱过氧化杂质限度
已经有1人回复
2楼2023-05-10 20:00:09